Autonomic nervous system testing may not distinguish multiple system atrophy from Parkinson's disease

D.E. Riley; T.C. Chelimsky
January 2003
Journal of Neurology, Neurosurgery & Psychiatry;Jan2003, Vol. 74 Issue 1, p56
Academic Journal
No abstract available.


Related Articles

  • Is clonodine-growth hormone stimulation a good test to differentiate multiple system atrophy from idiopathic Parkinson's disease? Mathias, C. J.; Kimber, J.; Watson, L.; Muthane, U. // Journal of Neurology;Apr2002, Vol. 249 Issue 4, p488 

    This article presents a letter to the editor regarding the use of clonidine-growth hormone stimulation as a test to differentiate multiple system atrophy from idiopathic Parkinson's disease.

  • Parkinson's Disease.  // Current Medical Literature: Neurology;2007, Vol. 23 Issue 2, p44 

    The author reviews several studies on Parkinson's disease. They include "Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease," by R. Zanettini and colleagues, "Multiple System Atrophy is Distinguished From Idiopathic Parkinson's Disease by the Arginine Growth Hormone...

  • Ambulatory Autonomic Testing in Multiple System Atrophy and Parkinson's Disease. Henchcliffe, Claire // Neurology Alert;Feb2017, Vol. 36 Issue 6, p45 

    A comparison of ambulatory blood pressure monitoring with tilt-table testing in 23 patients with multiple system atrophy, 18 with Parkinson's disease and autonomic dysfunction, and 33 with Parkinson's disease alone demonstrated 82% sensitivity and 100% specificity in detecting orthostatic...

  • Phosphorylated α-synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy. Zange, Leonora; Noack, Cornelia; Hahn, Katrin; Stenzel, Werner; Lipp, Axel // Brain: A Journal of Neurology;Aug2015, Vol. 138 Issue 8, p2310 

    Deposition of phosphorylated SNCA (also known as α-synuclein) in cutaneous nerve fibres has been shown pre- and post-mortem in Parkinson's disease. Thus far, no pre-mortem studies investigating the presence of phosphorylated SNCA in skin sympathetic nerve fibres of multiple system atrophy,...

  • Scintigraphic differentiation between two forms of primary dysautonomia early after onset of autonomic dysfunction: value of cardiac and pulmonary iodine-123 MIBG uptake. Reinhardt, Michael J.; J�ngling, Freimut D.; Krause, Thomas M.; Braune, Stefan // European Journal of Nuclear Medicine;2000, Vol. 27 Issue 5, p595 

    Primary dysfunction of the autonomic nervous system can be observed in patients with Parkinson�s disease and those with multiple system atrophy. However, the fate of the two diseases differs considerably and leads to different strategies for patient management. Differentiation of the two...

  • Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson’s disease and other synucleinopathies. Goldstein, David S.; Holmes, Courtney; Sharabi, Yehonatan // Brain: A Journal of Neurology;Jun2012, Vol. 135 Issue 6, p1900 

    Central catecholamine deficiency characterizes α-synucleinopathies such as Parkinson’s disease. We hypothesized that cerebrospinal fluid levels of neuronal metabolites of catecholamines provide neurochemical biomarkers of these disorders. To test this hypothesis we measured...

  • Clinical features and autonomic testing predict survival in multiple system atrophy. Coon, Elizabeth A.; Sletten, David M.; Suarez, Mariana D.; Mandrekar, Jay N.; Ahlskog, J. Eric; Bower, James H.; Matsumoto, Joseph Y.; Silber, Michael H.; Benarroch, Eduardo E.; Fealey, Robert D.; Sandroni, Paola; Low, Phillip A.; Singer, Wolfgang // Brain: A Journal of Neurology;12/1/2015, Vol. 138 Issue 12, p3623 

    Multiple system atrophy is characterized by autonomic failure along with motor symptoms of parkinsonism and/or cerebellar ataxia. There are differing reports on the influence of certain clinical features, including motor subtype (multiple system atrophy-parkinsonism versus multiple system...

  • P25α immunoreactivity in multiple system atrophy and Parkinson disease. Jellinger, Kurt A. // Acta Neuropathologica;Jul2006, Vol. 112 Issue 1, p112 

    A letter to the editor is presented in response to the article "P25α immunoreactivity in multiple system atrophy and Parkinson disease" by KG Baker in the May 11, 2006 issue.

  • Autonomic dysfunction in Parkinson's disease. Micieli, G.; Tosi, P.; Marcheselli, S.; Cavallini, A. // Neurological Sciences;May2003 Supplement 1, Vol. 24, ps32 

    Autonomic dysfunction in patients with Parkinson's disease (PD) has been recognized since the original description by James Parkinson in 1817. Autonomic failure can be the clinical presentation of other diseases like pure autonomic failure (PAF) and multiple system atrophy (MSA). Both the...

  • Dysautonomias: clinical disorders of the autonomic nervous system. Goldstein, David S.; Robertson, David; Esler, Murray; Straus, Stephen E.; Eisenhofer, Graeme // Annals of Internal Medicine;11/5/2002, Vol. 137 Issue 9, p753 

    The term dysautonomia refers to a change in autonomic nervous system function that adversely affects health. The changes range from transient, occasional episodes of neurally mediated hypotension to progressive neurodegenerative diseases; from disorders in which altered autonomic function plays...


Read the Article


Sign out of this library

Other Topics